Literature DB >> 26222284

pH-sensitive polymer-liposome-based antigen delivery systems potentiated with interferon-γ gene lipoplex for efficient cancer immunotherapy.

Eiji Yuba1, Yuhei Kanda1, Yuta Yoshizaki1, Ryoma Teranishi1, Atsushi Harada1, Kikuya Sugiura2, Takeshi Izawa2, Jyoji Yamate2, Naoki Sakaguchi3, Kazunori Koiwai3, Kenji Kono4.   

Abstract

Potentiation of pH-sensitive liposome-based antigen carriers with IFN-γ gene lipoplexes was attempted to achieve efficient induction of tumor-specific immunity. 3-Methylglutarylated poly(glycidol) (MGluPG)-modified liposomes and cationic liposomes were used, respectively, for the delivery of antigenic protein ovalbumin (OVA) and IFN-γ-encoding plasmid DNA (pDNA). The MGluPG-modified liposomes and the cationic liposome-pDNA complexes (lipoplexes) formed hybrid complexes via electrostatic interactions after their mixing in aqueous solutions. The hybrid complexes co-delivered OVA and IFN-γ-encoding pDNA into DC2.4 cells, a murine dendritic cell line, as was the case of MGluPG-modified liposomes for OVA or the lipoplexes for pDNA. Both the lipoplexes and the hybrid complexes transfected DC2.4 cells and induced IFN-γ protein production, but transfection activities of the hybrid complexes were lower than those of the parent lipoplexes. Subcutaneous administration of hybrid complexes to mice bearing E.G7-OVA tumor reduced tumor volumes, which might result from the induction of OVA-specific cytotoxic T lymphocytes (CTLs). However, the hybrid complex-induced antitumor effect was the same level of the MGluPG-modified liposome-mediated antitumor immunity. In contrast, an extremely strong antitumor immune response was derived when these liposomes and lipoplexes without complexation were injected subcutaneously at the same site of tumor-bearing mice. Immunohistochemical analysis of tumor sections revealed that immunization through the liposome-lipoplex combination promoted the infiltration of CTLs to tumors at an early stage of treatment compared with liposomes, resulting in strong therapeutic effects.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer immunotherapy; Cellular immunity; Dendritic cell; Interferon-γ; Lipoplex; pH-sensitive liposome

Mesh:

Substances:

Year:  2015        PMID: 26222284     DOI: 10.1016/j.biomaterials.2015.07.031

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  13 in total

Review 1.  Stimuli-responsive liposomes for drug delivery.

Authors:  Y Lee; D H Thompson
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2017-02-15

2.  siRNA Design and Delivery Based on Carbon Nanotubes.

Authors:  Danyang Li; Khuloud T Al-Jamal
Journal:  Methods Mol Biol       Date:  2021

Review 3.  Liposomal delivery of CRISPR/Cas9.

Authors:  Shuai Zhen; Xu Li
Journal:  Cancer Gene Ther       Date:  2019-11-02       Impact factor: 5.987

4.  Development Of Novel Liposome-Encapsulated Combretastatin A4 Acylated Derivatives: Prodrug Approach For Improving Antitumor Efficacy.

Authors:  Yongwei Gu; Juanjuan Ma; Zhiqin Fu; Youfa Xu; Baoan Gao; Jianzhong Yao; Wei Xu; Kedan Chu; Jianming Chen
Journal:  Int J Nanomedicine       Date:  2019-11-07

Review 5.  Recent Advances in Subunit Vaccine Carriers.

Authors:  Abhishek Vartak; Steven J Sucheck
Journal:  Vaccines (Basel)       Date:  2016-04-19

Review 6.  Engineering nanoparticles to overcome barriers to immunotherapy.

Authors:  Randall Toy; Krishnendu Roy
Journal:  Bioeng Transl Med       Date:  2016-06-20

Review 7.  Advanced biomaterials for cancer immunotherapy.

Authors:  Fan Yang; Kun Shi; Yan-Peng Jia; Ying Hao; Jin-Rong Peng; Zhi-Yong Qian
Journal:  Acta Pharmacol Sin       Date:  2020-03-02       Impact factor: 6.150

Review 8.  Bioactive Nanoparticles for Cancer Immunotherapy.

Authors:  Suchithra Poilil Surendran; Myeong Ju Moon; Rayoung Park; Yong Yeon Jeong
Journal:  Int J Mol Sci       Date:  2018-12-04       Impact factor: 5.923

9.  Current applications and future prospects of nanotechnology in cancer immunotherapy.

Authors:  Sen Yan; Peng Zhao; Tingting Yu; Ning Gu
Journal:  Cancer Biol Med       Date:  2019-08       Impact factor: 4.248

Review 10.  Interferon-γ: teammate or opponent in the tumour microenvironment?

Authors:  Angela M Gocher; Creg J Workman; Dario A A Vignali
Journal:  Nat Rev Immunol       Date:  2021-06-21       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.